PW Medtech GroupFRA:PWE 84 PS Ratio is 1.61 as of Jul. 12, 2026, which is 64% below its 10-year median of 4.44. GuruFocus rates FRA:PWE with a GF Score™ of 84/100 and a GF Value™ of €0.13. The stock has 7 warning signs investors should review. Among 805 Medical Devices & Instruments companies, PW Medtech Group ranks better than 64.22% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, PW Medtech Group's share price is €0.106.
PW Medtech Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.07. Hence, PW Medtech Group's PS Ratio for today is 1.61.
Good Sign:
PW Medtech Group Ltd stock PS Ratio (=1.79) is close to 2-year low of 1.69.
The historical rank and industry rank for PW Medtech Group's PS Ratio or its related term are showing as below:
FRA:PWE'
s PS Ratio Range Over the Past 10 Years
Min: 1.33 Med: 4.44 Max: 11.93
Current: 1.8
During the past 13 years, PW Medtech Group's highest PS Ratio was 11.93. The lowest was 1.33. And the median was 4.44.
FRA:PWE's PS Ratio is ranked better than 64.22% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 2.94
vs FRA:PWE: 1.80
PW Medtech Group Ltd revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of PW Medtech Group was 13.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 16.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 28.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 8.80% per year.
During the past 13 years, PW Medtech Group's highest 3-Year average Revenue per Share Growth Rate was 36.20% per year. The lowest was -21.70% per year. And the median was 5.30% per year.
Back to Basics: PS Ratio
PW Medtech Group (FRA:PWE) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
PW Medtech Group PS Ratio Related Terms
PW Medtech Group PS Ratio Historical Data
* Premium members only.
The historical data trend for PW Medtech Group's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, PW Medtech Group's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PW Medtech Group PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PW Medtech Group's PS Ratio distribution charts can be found below:
* The bar in red indicates where PW Medtech Group's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
PW Medtech Group's Share Price of today is €0.106.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PW Medtech Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.07.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PW Medtech Group (FRA:PWE) has a PS Ratio of 1.61 as of Jul. 12, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on PW Medtech Group and its competitors. This is 64% below median its historical median of 4.44. Over the past decade, PW Medtech Group's PS Ratio has ranged from 1.33 to 11.93. According to the industry distribution chart, PW Medtech Group ranks #288 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 35.8%.
Is PW Medtech Group's PS Ratio too high?
PW Medtech Group's current PS Ratio of 1.61 is 64% below median its 10-year median of 4.44. Over the past 10 years, this metric has ranged from a low of 1.33 to a high of 11.93. The Medical Devices & Instruments industry median PS Ratio is 2.94. PW Medtech Group's value of 1.61 is 45.2% below this industry median. Based on the distribution chart, PW Medtech Group ranks #288 out of 805 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, PW Medtech Group has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does PW Medtech Group's PS Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, PW Medtech Group ranks #288 out of 805 companies for PS Ratio. This puts PW Medtech Group in the upper half of its industry. The industry median PS Ratio is 2.94. PW Medtech Group's value of 1.61 is 45.2% below this benchmark. Historically, PW Medtech Group's own PS Ratio has ranged from 1.33 to 11.93 over the past decade. While the company's 10-year median is 4.44 vs. the industry median of 2.94, PW Medtech Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.94, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PW Medtech Group's current PS Ratio of 1.61 is 45.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on PW Medtech Group and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PW Medtech Group's current PS Ratio is 1.61, which is 64% below median its own 10-year median of 4.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PW Medtech Group stock overvalued right now?
PW Medtech Group (FRA:PWE) has a current PS Ratio of 1.61. The stock's GF Value™ is €0.13, compared to a current price of €0.11 — trading 18.5% below its estimated fair value. The current PS Ratio is 1.61, which is 64% below median its 10-year median of 4.44 and 45.2% below the Medical Devices & Instruments industry median of 2.94. PW Medtech Group's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For PW Medtech Group (FRA:PWE), the current PS Ratio is 1.61 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PW Medtech Group (FRA:PWE) Overvalued in 2026?
Based on GuruFocus' analysis, PW Medtech Group stock appears to be undervalued.
The current stock price of €0.11 is trading 18.5% below its estimated GF Value™ of €0.13.
Key valuation signals for FRA:PWE:
PS Ratio: 1.61 (64% below median its 10-year median of 4.44)
GF Value™: €0.13 vs. price of €0.11 (18.5% below fair value)
Industry Position: 45.2% below the Medical Devices & Instruments median (#288 of 805)
No single metric tells the full story. See the FRA:PWE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PW Medtech Group Ltd is a medical device company focused on China's medical device industry. The Group operates in infusion sets, blood purification products, and regenerative medical biomaterials. Its products include non-PVC-based infusion sets, precision filter infusion sets, light-resistant infusion sets, intravenous cannula products, insulin needles and pens, high flux and low flux hemodialyzers, hemodiafilters, hemoperfutors, and dialysis machines. Its segments are Infusion Set Business, Blood Purification Business, which represents the R&D, manufacturing, and sales of hemodialysis and blood purification medical devices, and Regenerative Medical Biomaterials Business, which generates maximum revenue. Geographically, it operates in China, North America, India and Others.
84GF Score
Get the complete analysis for FRA:PWE
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PWE has been successfully added to your 
